Azenta (NASDAQ:AZTA) Stock Price Target Raised at Jefferies Financial Group

Azenta (NASDAQ:AZTA) had its price target lifted by stock analysts at Jefferies Financial Group from $44.00 to $52.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Jefferies Financial Group‘s price objective indicates a potential upside of 6.45% from the company’s current price.

Several other equities research analysts also recently issued reports on the company. Weiss Ratings upgraded Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 26th. Wall Street Zen cut Azenta from a “buy” rating to a “hold” rating in a report on Sunday, October 18th. Finally, Needham & Company LLC restated a “buy” rating and set a $37.00 target price on shares of Azenta in a report on Monday, September 14th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Azenta has a consensus rating of “Hold” and a consensus target price of $43.60.

Azenta Trading Up 20.7%

Azenta stock traded up $8.37 during trading on Wednesday, hitting $48.85. The company had a trading volume of 1,469,773 shares, compared to its average volume of 940,984. Azenta has a 1-year low of $15.93 and a 1-year high of $50.06. The company’s 50 day simple moving average is $35.64 and its 200-day simple moving average is $28.47. The stock has a market cap of $2.14 billion, a price-to-earnings ratio of -17.71 and a beta of 1.47.

Azenta (NASDAQ:AZTA) last released its quarterly earnings results on Tuesday, November 10th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.17. Azenta had a positive return on equity of 1.18% and a negative net margin of 20.63%. The company had revenue of $167.09 million for the quarter, compared to analysts’ expectations of $160.16 million.

Institutional Trading of Azenta

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of Azenta in the second quarter valued at $192,152,000. Allspring Global Investments Holdings LLC grew its stake in Azenta by 16.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,613,914 shares of the company’s stock worth $34,183,000 after purchasing an additional 225,867 shares in the last quarter. Front Street Capital Management Inc. acquired a new position in Azenta during the 2nd quarter worth $33,212,000. American Capital Management Inc. grew its stake in Azenta by 26.9% during the 1st quarter. American Capital Management Inc. now owns 1,296,024 shares of the company’s stock worth $27,385,000 after purchasing an additional 274,588 shares in the last quarter. Finally, GW&K Investment Management LLC increased its holdings in Azenta by 0.4% during the 3rd quarter. GW&K Investment Management LLC now owns 992,616 shares of the company’s stock worth $34,633,000 after purchasing an additional 4,187 shares during the period. 99.08% of the stock is currently owned by institutional investors and hedge funds.

More Azenta News

These are some of the AZTA news items that stood out recently:

• Positive Sentiment: Azenta reported fourth-quarter EPS of $0.28, beating the $0.11 consensus estimate, while revenue of $167.09 million also topped expectations of $160.16 million. Azenta fiscal 2026 results
• Positive Sentiment: Share repurchases and a sizable cash position add to the potential turnaround case: Azenta repurchased 4.4 million shares for $118.2 million in fiscal 2026 and ended the year with $506 million in cash and marketable securities, with no debt reported in the cited balance-sheet update. Healthcare stocks and Azenta buybacks
• Negative Sentiment: A law firm says it is investigating potential securities claims alleging Azenta may have issued materially misleading business information. The investigation is not a finding of wrongdoing, but could add uncertainty for investors. Securities claims investigation

Azenta Company Profile

Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.